Skip to main content
. 2020 Aug 26;5(4):e000787. doi: 10.1136/esmoopen-2020-000787

Table 5.

Adjuvant regimens administered

Total
(n=43)
N (%)
Adjuvant treatment regimens
 Paclitaxel 12 (27.9)
 Doxorubicin+ifosfamide 6 (14.0)
 Gemcitabine+docetaxel 6 (14.0)
 Gemcitabine+docetaxel+doxorubicin+ifosfamide 5 (11.6)
 Doxorubicin 3 (7.0)
 Gemcitabine 2 (4.7)
 Cisplatin 2 (4.6)
 Docetaxel 1 (2.3)
 Ifosfamide 1 (2.3)
 Caelyx 1 (2.3)
 Epirubicine 1 (2.3)
 Temozolomide 1 (2.3)
 Vincristine+dacarbazine 1 (2.3)
 Vinorelbine 1 (2.3)